哈哈中國哈哈
媒體來源: 美國化學學會 化學與工程新聞
完整新聞標題: GSK to end neuroscience R&D in China
葛蘭素藥廠將終止在上海的神經科學研發實驗室
Shanghai was once the hub of the company’s neuroscience
research effort.
By Jean-François Tremblay
摘要: 葛蘭素藥廠原本在上海的實驗室專門負責研究帕金森氏症，阿茲海默症，
以及多發性硬化症。在經歷了一些挫折阻礙之後，決定將原本在上海的實
驗室移往美國賓州。
2007年進軍上海的時候曾經誓言要建立中國最大的研發中心，但在2013年
時爆發了疑似論文造假的醜聞(原文謂圖片標錯)，開除了研發總監臧敬武，
2014年又發生了該公司賄絡醫生，唆使醫生開處方時使用葛蘭素的藥的醜
聞，因此向中國政府支付了5億美元(30億人民幣)的罰金。
3.完整新聞內文:
(以下不專業翻譯，懇請鄉民們不吝幫忙校正)
It wasn’t long ago that GlaxoSmithKline’s Shanghai lab led the firm’s
research efforts in neurological diseases including Parkinson’s, multiple
sclerosis, and Alzheimer’s. Now, after years of setbacks in China, the
company is ending neuroscience R&D in Shanghai.
不久之前葛蘭素藥廠在上海的實驗室是公司主要負責神經科學研究的地方，在經過這
幾年的一些挫折之後，藥廠決定將關閉在上海的實驗室。
“Following a portfolio review and prioritization, we have decided to close
our neuroscience R&D center in Shanghai and move key programs to our global
R&D hub in Upper Providence [Pa.] in the U.S., where they will benefit from
colocation with other pipeline R&D programs,” GSK says.
葛蘭素表示，在審視業務組合和決定業務的優先順序之後，決定將上海的實驗室關閉，
並將重要的單位般回美國賓州，如此一來在賓州的單位將因為和公司的產線靠近，而有
一些地緣上的優勢。
GSK announced plans to invest in Shanghai in 2007, saying it would build China
’s largest R&D center operated by a multinational drug firm. To focus on
neurological disorders, the center was to be staffed by hundreds of
scientists under the guidance of Jingwu Zang, a leading multiple sclerosis
researcher.
葛蘭素是在2007年發布將投資上海的計畫，當時曾希望建立一個全中國最大的研發中心，
並且專注在神經科學研究方面。當時預定雇用上百名科學家，並會在一位研究多發性硬
化症有名望的科學家臧敬武的領導下進行研究。
In 2013, however, GSK fired Zang after a paper he coauthored and published in
Nature Medicine was found to contain mislabeled data. At the time, Zang
vehemently denied research fraud and claimed that he and coauthors had made
an inadvertent error. After the firing, GSK was soon embroiled in a much
greater controversy.
然而2013年時，臧做為通訊作者，發表在Nature Medicine上的論文被發現數據標示有誤
因而被開除，臧曾嚴正表示絕無造假，並且說明共同作者們犯的錯誤皆是無心之過。在開
除臧之後，葛蘭素旋即被捲入另一更具爭議的事件。
After a long saga that included the discovery of video cameras in the bedroom
of the company’s China head, GSK apologized in September 2014 and paid a
fine of $500 million to the Chinese government for bribing doctors to
prescribe the company’s drugs. The following year GSK laid off 110 of its
China staffers for alleged ethical violations.
在經歷了包含發現葛蘭素公司中國區總裁臥室裡有錄影機等諸事之後，葛蘭素公司在2014
年承認其向醫生行賄開藥方的醜事，道歉並向中國政府支付了5億美元的罰金。隔年葛蘭素
開除了涉及此違規事件的110名員工。
Last year, Min Li, who replaced Zang as head of neuroscience in Shanghai,
publicly stated that GSK remained committed to its China neuroscience
research. “By setting up our R&D structure in this way, we are committed not
only to patients in China but also to talent in China,” the newspaper China
Daily quoted him as saying.
去年(2016)接任臧敬武職位的Li Min公開說明葛蘭素公司依然將在中國發展神經科學研究
視為重要任務，中國日報刊載Li Min所說的話：「透過這樣建立研發機構的方式，我們不
僅盡到(照顧)中國的病人有責任，也盡到對中國的人才的責任。」
Despite the retreat from neuroscience, drug R&D will go on in China, GSK
insists. “The China R&D development organization will continue to be based
in Shanghai and is set to expand over the next two years to accelerate the
development of new medicines,” the firm says. “We remain committed to China
and will focus our R&D efforts in China on the needs of China, at both our
Shanghai site and our Institute for Infectious Diseases & Public Health in
Beijing.”
儘管葛蘭素在中國的研發重心將偏離神經科學研究，藥物研發將在中國繼續進行。葛蘭素
公司堅稱：「在中國的研發中心依然會在上海，接下來的兩年會進行擴張好能加速新藥
研發」該公司亦表示：「我們依然很重視在中國上海的單位和在北京的流行病與公衛機構
。」
4.完整新聞連結 (或短網址):
http://cen.acs.org/articles/95/web/2017/08/GSK-end-neuroscience-RD-China.html
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 75.72.148.79
※ 文章網址: https://www.ptt.cc/bbs/Gossiping/M.1503634619.A.249.html
※ 編輯: FD56 (75.72.148.79), 08/25/2017 12:17:18
噓
08/25 12:18, , 1F
08/25 12:18, 1F
推
08/25 12:22, , 2F
08/25 12:22, 2F
推
08/25 12:25, , 3F
08/25 12:25, 3F
→
08/25 12:26, , 4F
08/25 12:26, 4F
→
08/25 12:26, , 5F
08/25 12:26, 5F
→
08/25 12:26, , 6F
08/25 12:26, 6F
※ 編輯: FD56 (75.72.148.79), 08/25/2017 12:34:12
推
08/25 12:36, , 7F
08/25 12:36, 7F
推
08/25 12:51, , 8F
08/25 12:51, 8F